<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04863638</url>
  </required_header>
  <id_info>
    <org_study_id>BIBP2020004CN</org_study_id>
    <nct_id>NCT04863638</nct_id>
  </id_info>
  <brief_title>A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated</brief_title>
  <acronym>COVID-19</acronym>
  <official_title>A Immunobridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated in Population Aged ≥ 60 Years Old and 3-17 Years Old Compared With That in Population Aged 18-59 Years Old</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Biotec Group Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Institute of Biological Products Co Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>China National Biotec Group Company Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is a randomized study to evaluate the immunogenicity of COVID-19 Vaccine (Vero&#xD;
      Cell), Inactivatedand in population aged 60 years old and 3-17 years old with different&#xD;
      3-dose schedules compared to that in population aged 18-59 years old with 2-dose schedule.&#xD;
      And subjects in the same age are randomly assigned to different immunization schedule groups.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This trial is a randomized study to evaluate the immunogenicity of COVID-19 Vaccine (Vero&#xD;
      Cell), Inactivatedand in population aged 60 years old and 3-17 years old with different&#xD;
      3-dose schedules (D0,21,42, D0, 21,111,or D0,21,171)compared to that in population aged 18-59&#xD;
      years old with 2-dose schedule (D0,21). And subjects in the same age are randomly assigned to&#xD;
      different immunization schedule groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Geometric Mean Titer (GMT) of anti-SARS-CoV-2 neutralizing antibody</measure>
    <time_frame>14 days after the full course immunization</time_frame>
    <description>Neutralizing antibody assay will be performed using the Microcytopathic assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The four-fold increase rate of anti-SARS-CoV-2 neutralizing antibody</measure>
    <time_frame>14 days after the full course immunization</time_frame>
    <description>≥4 fold increase from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Geometric Mean Titer (GMT) of anti-SARS-CoV-2 neutralizing antibody</measure>
    <time_frame>14 days after the second dose in schedule of Day 0,21,42</time_frame>
    <description>Neutralizing antibody assay will be performed using the Microcytopathic assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The four-fold increase rate of anti-SARS-CoV-2 neutralizing antibody</measure>
    <time_frame>14 days after the second dose in schedule of Day 0,21,42</time_frame>
    <description>≥4 fold increase from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Geometric Mean Titer (GMT) of anti-SARS-CoV-2 neutralizing antibody</measure>
    <time_frame>before the third dose in schedules of Day 0,21,111 and Day 0,21,171</time_frame>
    <description>Neutralizing antibody assay will be performed using the Microcytopathic assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The four-fold increase rate of anti-SARS-CoV-2 neutralizing antibody</measure>
    <time_frame>before the third dose in schedules of Day 0,21,111 and Day 0,21,171</time_frame>
    <description>≥4 fold increase from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Persistence</measure>
    <time_frame>3 months, 6 months, 12 months after the full course immunization</time_frame>
    <description>Neutralizing antibody assay will be performed using the Microcytopathic assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety index-Incidence of adverse reactions</measure>
    <time_frame>From the beginning of the vaccination to 28 days after the full course immunization</time_frame>
    <description>collect the all the adverse events using dairy card and contact card</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety index-Incidence of serious adverse events</measure>
    <time_frame>From the beginning of the vaccination to 6 months after the full course immunization</time_frame>
    <description>All SAEs will be collected</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immune Persistence</measure>
    <time_frame>18 months and 24 months after the full immunization</time_frame>
    <description>Neutralizing antibody assay will be performed using the Microcytopathic assay</description>
  </other_outcome>
  <number_of_arms>18</number_of_arms>
  <enrollment type="Anticipated">4400</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>A1 aged ≥ 71</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 subjects age ≥ 71 （A1）receive 3 doses of vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A2 aged ≥ 71</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 subjects age ≥ 71 （A2）receive 3 doses of vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A3 aged ≥ 71</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 subjects age ≥ 71 (A3) receive 3 doses of vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B1 aged 60-70</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 subjects age 60-70 (B1) receive 3 doses of vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B2 aged 60-70</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 subjects age 60-70 (B2) receive 3 doses of vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B3 aged 60-70</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 subjects age 60-70 (B3) receive 3 doses of vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1 aged 18-59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 subjects age 18-59 (C1) receive 3 doses of vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2 aged 18-59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 subjects age 18-59 (C2) receive 3 doses of vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C3 aged 18-59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 subjects age 18-59 (C3) receive 3 doses of vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C4 aged 18-59</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 subjects age 18-59 (C4) receive 2 doses of vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D1 aged 9-17</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 subjects age 9-17 (D1) receive 3 doses of vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D2 aged 9-17</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 subjects age 9-17 (D2) receive 3 doses of vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D3 aged 9-17</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 subjects age 9-17 （D3）receive 3 doses of vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D4 aged 9-17</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 subjects age 9-17 （D4）receive 2 doses of vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E1 aged 3-8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 subjects age 3-8 （E1） receive 3 doses of vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E2 aged 3-8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 subjects age 3-8 （E2）receive 3 doses of vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E3 aged 3-8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 subjects age 3-8 （E3）receive 3 doses of vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E4 aged 3-8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 subjects age 3-8 （E4）receive 2 doses of vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated</intervention_name>
    <description>the schedule of Day 0, 21, 42</description>
    <arm_group_label>A1 aged ≥ 71</arm_group_label>
    <arm_group_label>B1 aged 60-70</arm_group_label>
    <arm_group_label>C1 aged 18-59</arm_group_label>
    <arm_group_label>D1 aged 9-17</arm_group_label>
    <arm_group_label>E1 aged 3-8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated</intervention_name>
    <description>the schedule of Day 0, 21, 111</description>
    <arm_group_label>A2 aged ≥ 71</arm_group_label>
    <arm_group_label>B2 aged 60-70</arm_group_label>
    <arm_group_label>C2 aged 18-59</arm_group_label>
    <arm_group_label>D2 aged 9-17</arm_group_label>
    <arm_group_label>E2 aged 3-8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated</intervention_name>
    <description>the schedule of Day 0, 21, 171</description>
    <arm_group_label>A3 aged ≥ 71</arm_group_label>
    <arm_group_label>B3 aged 60-70</arm_group_label>
    <arm_group_label>C3 aged 18-59</arm_group_label>
    <arm_group_label>D3 aged 9-17</arm_group_label>
    <arm_group_label>E3 aged 3-8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2 doses of vaccine</intervention_name>
    <description>the schedule of Day 0, 21</description>
    <arm_group_label>C4 aged 18-59</arm_group_label>
    <arm_group_label>D4 aged 9-17</arm_group_label>
    <arm_group_label>E4 aged 3-8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 3 years and above (after enrolled, subjects will be allocated according to age).&#xD;
&#xD;
          -  By asking for medical history and physical examination, the health condition judged by&#xD;
             the investigators is well.&#xD;
&#xD;
          -  Female subjects of childbearing age are not nursing or pregnant at the time of&#xD;
             enrolment (negative urine pregnancy test) and have no family planning within the first&#xD;
             3 months after enrolment. Effective contraceptive measures have been taken within 2&#xD;
             weeks before inclusion.&#xD;
&#xD;
          -  No vaccination history of COVID-19 vaccine before enrollment.&#xD;
&#xD;
          -  Be able and willing to complete the whole prescribed study plan.&#xD;
&#xD;
          -  With self-ability to understand the study procedures, the informed consent &amp;&#xD;
             voluntarily sign an informed consent form and be able to comply with the requirements&#xD;
             of the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Confirmed cases, suspected cases or asymptomatic infections of SAR-CoV-2 infection&#xD;
             (check &quot;China Disease Prevention and Control Information System&quot;).&#xD;
&#xD;
          -  Has a history of SARS, MERS infection (self-report, on-site inquiry).&#xD;
&#xD;
          -  &gt;14-year-old subjects axillary temperature ≥37.3℃, ≤14-year-old subjects axillary&#xD;
             temperature ≥37.5℃.&#xD;
&#xD;
          -  Previous severe allergic reactions to vaccination (such as acute allergic reactions,&#xD;
             urticaria, dyspnea, angioneurotic edema or abdominal pain) or allergy to known&#xD;
             ingredients of inactivated SARS-CoV-2 vaccine have occurred.&#xD;
&#xD;
          -  With severe liver diseases, severe kidney diseases, uncontrollable hypertension&#xD;
             (systolic blood pressure ≥160 mmHg, diastolic blood pressure ≥100 mmHg), diabetic&#xD;
             complications, malignant tumors, various acute diseases, or acute attack period of&#xD;
             chronic diseases.&#xD;
&#xD;
          -  Has been diagnosed with congenital or acquired immune deficiency, HIV infection,&#xD;
             lymphoma, leukemia or other autoimmune diseases.&#xD;
&#xD;
          -  Has a history of convulsion, epilepsy, encephalopathy or mental illness or family&#xD;
             history.&#xD;
&#xD;
          -  With congenital malformations or developmental disorders, genetic defects, severe&#xD;
             malnutrition, etc.&#xD;
&#xD;
          -  Has a history of coagulation dysfunction (e.g. Coagulation factor deficiency,&#xD;
             coagulation disease).&#xD;
&#xD;
          -  Received immunotherapy or inhibitor therapy within 3 months (continuous oral or&#xD;
             infusion for more than 14 days).&#xD;
&#xD;
          -  Received live attenuated vaccinewithin 1 month before this vaccination, other vaccines&#xD;
             are inoculated within 14 days before this vaccination.&#xD;
&#xD;
          -  Received blood products within 3 months before enrolment.&#xD;
&#xD;
          -  Received other research drugs within 6 months before enrolment.&#xD;
&#xD;
          -  Other circumstances judged by investigators are not suitable for this clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanxia Wang, Bachelor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henan Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yunkai Yang, Prof.</last_name>
    <phone>+8613601126881</phone>
    <email>yangyunkai@sinopharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yanjin County Center for Disease Control and Prevention</name>
      <address>
        <city>Xinxiang</city>
        <state>Henan</state>
        <zip>453200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guangjie Zhu</last_name>
      <phone>+8618637367986</phone>
      <email>zgj-jk2009@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 27, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>SARS-CoV-2 Vaccine</keyword>
  <keyword>Coronavirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

